Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

Author: Abhyankar Anita   Tapper Elliot   Bonder Alan  

Publisher: MDPI

E-ISSN: 1424-8247|7|1|18-28

ISSN: 1424-8247

Source: Pharmaceuticals, Vol.7, Iss.1, 2013-12, pp. : 18-28

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.

Related content